Francesco Marincola Departs Kite as Head of Cell Therapy Research; Yescarta Significantly Improved OS in 2L LBCL
On Tuesday, March 21, Sonata Therapeutics announced (press release) the CSO appointment of Francesco Marincola, former SVP and Global Head of Cell Therapy Research at Gilead (Kite). On the same day, Gilead (Kite) reported (press release) the primary overall survival (OS) data analysis of Yescarta’s (autologous CD19 CAR-T) Ph3 ZUMA-7 trial in 2L DLBCL demonstrating a significant OS improvement for Yescarta versus SOC. Below, Celltelligence provides insights on Marincola’s departure from Kite, while discussing how OS data could further support Yescarta’s leading position in the market.